50% U.S. Tariffs Hit Canadian Medical Tech From October 30

Canadian medical technologies, diagnostics and laboratory products now carry a 50 per cent tariff at the U.S. border. The duties, imposed under Section 338, took effect October 30 and capture a significant share of Canada's medical technology exports to the United States — goods that hospitals, laboratories and health care providers use daily.

Medtech Canada, the Mississauga-based industry association, didn't mince words. It says it is "very concerned" that products used to diagnose and treat patients are now caught in a trade dispute.

"Medical technologies should not be caught in the crossfire of a trade dispute," said Nicole DeKort, President and CEO of Medtech Canada. "A 50 per cent tariff on products used to diagnose and treat patients risks increasing costs for U.S. hospitals and laboratories, disrupting supply chains and ultimately impacting patient care."

Half again on top of the product price. That's what a U.S. hospital procurement team now faces on affected Canadian-made devices and diagnostics — before anyone has negotiated a single mitigation.

What does this change for shippers and health systems?

The core problem is structural, not transactional. Canada and the United States have built deeply integrated medical technology supply chains over decades. Components, sub-assemblies and finished products cross the border repeatedly on their way to a finished device. A 50 per cent duty applied at any one of those crossings compounds through the chain.

Replacement isn't a quick fix either. Many medical technologies are highly specialized and regulated, according to Medtech Canada, and cannot simply be swapped out without clinical evaluation, validation or training. A hospital can't reroute to an alternate supplier the way a retailer reroutes apparel. Regulatory approval timelines, not freight rates, set the pace.

That asymmetry matters for freight forwarders and logistics managers in this vertical. You can't arbitrage your way around a validated device. The cost lands where it lands.

The commercial logic cuts both ways

DeKort made a point that U.S. policymakers may want to reread: "Canada is an important customer for the U.S. medical technology industry. Tariffs that disrupt this integrated market risk creating costs and supply challenges on both sides of the border. Patients should not pay the price for a trade dispute."

In other words, this isn't a one-way extraction. U.S. medtech manufacturers sell into Canada, source components from Canada, and share supply chains with Canadian plants. Tariff friction in one direction tends to find its way back in the other.

The organization's broader verdict is blunt. Trade barriers between Canada and the United States risk weakening, rather than strengthening, the resiliency of the medical technology industry. A policy meant to build resilience that instead erodes it — there's the irony in a sentence.

The ask: zero-for-zero

Medtech Canada is backing the Global Medical Technology Alliance's call for reciprocal zero-for-zero tariffs on medical technologies. The formula is simple: both countries drop tariffs on these goods entirely, and the sector exits the trade fight altogether.

It's not a novel concept — zero-for-zero arrangements have insulated sensitive goods categories in past trade negotiations. Whether Washington has any appetite for one under Section 338 is another question entirely.

Medtech Canada says it will keep working with the Government of Canada and other partners to protect patient access and maintain resilient North American medical technology supply chains. Expect lobbying to intensify, and expect U.S. hospital and laboratory groups — the ones absorbing the tariff bill — to add their weight to the zero-for-zero push in the weeks ahead.

By Amara Osei